Raphaelle Porcu

Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.

M. Morris, A. Armstrong, C. Higano, 2020 .

Title : A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with 2 Metastatic Castration-Resistant Prostate Cancer 3

M. Morris, A. Armstrong, C. Higano, 2021 .

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

M. Morris, A. Armstrong, C. Higano, 2021, Clinical Cancer Research.